Humacyte (HUMA) Equity Average (2020 - 2026)
Humacyte (HUMA) reported Equity Average of $7.4 million for Q1 2026, up 188.61% year-over-year from $2.6 million in Q1 2025, and up 997.26% quarter-over-quarter from -$821000.0 in Q4 2025.
Humacyte (HUMA) Equity Average (2020 - 2026) Analysis & Trends
Humacyte (HUMA) has 7 years of Equity Average data on file, last reported at $7.4 million in Q1 2026.
- Equity Average for Q1 2026 came in at $7.4 million, up 188.61% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.4 million (up 188.61% YoY), and the FY2025 annual result was -$24.8 million, down 26.68% from the prior year.
- Equity Average advanced to $7.4 million in Q1 2026 per HUMA's latest filing, from -$821000.0 in the prior quarter.
- Over five years, Equity Average peaked at $130.5 million in Q3 2022 and troughed at -$58.2 million in Q4 2024.
- A 5-year average of $38.9 million and a median of $20.0 million in 2025 frame the typical range for Equity Average.
- The sharpest annual moves came in 2024 and 2025: Equity Average plunged 330.3% in 2024, then jumped 1977.99% in 2025.
- A 5-year view of Equity Average shows it stood at $117.8 million in 2022, then plunged by 78.55% to $25.3 million in 2023, then sank by 330.3% to -$58.2 million in 2024, then jumped by 98.59% to -$821000.0 in 2025, then surged by 997.26% to $7.4 million in 2026.
- Business Quant data shows HUMA's Equity Average at $7.4 million in Q1 2026, -$821000.0 in Q4 2025, and -$349500.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | 3.50 Bn |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | 783.14 Mn |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | 3.76 Mn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 1.01 Bn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | 21.35 Mn |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 19.01 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | 516.41 Mn |
| 10 | Humacyte | 267.09 Mn | 218.55 Mn | -1.54 Mn | 7.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.37 Mn |
| Dec 31, 2025 | -821,000.00 |
| Sep 30, 2025 | -349,500.00 |
| Jun 30, 2025 | 20.05 Mn |
| Mar 31, 2025 | -8.31 Mn |
| Dec 31, 2024 | -58.20 Mn |
| Sep 30, 2024 | -46.00 Mn |
| Jun 30, 2024 | -1.07 Mn |
| Mar 31, 2024 | 19.85 Mn |
| Dec 31, 2023 | 25.27 Mn |
| Sep 30, 2023 | 49.06 Mn |
| Jun 30, 2023 | 71.50 Mn |
| Mar 31, 2023 | 99.41 Mn |
| Dec 31, 2022 | 117.80 Mn |
| Sep 30, 2022 | 130.47 Mn |
| Jun 30, 2022 | 123.08 Mn |
| Mar 31, 2022 | 113.03 Mn |
| Dec 31, 2021 | 99.02 Mn |
| Sep 30, 2021 | -151.95 Mn |
| Jun 30, 2021 | -372.64 Mn |